Patients with higher MK expression have shorter survival time than those with lower MK expression.

MK表达与膀胱癌术后患者的预后相关，MK呈高表达者的生存时间比低表达者短。

youdao

Among those PPAR drugs in development, Merck's MK-767 was believed to be farthest along.

FORBES: Magazine Article

By late 1996 Merck began human tests of its leading compound, called MK-869, in depressed patients.

FORBES: Betting on the brain

The experimental agent called nivolumab and Merck's drug, known as MK-3475, each work against a different mechanism called PD-1.

WSJ: New Cancer Drugs Harness Power of Immune System